Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 6 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1649 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a potential US$251 M deal, Exelixis has granted Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS